HeartBeam Inc. (NASDAQ: BEAT) announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses. The transaction, completed on April 16, 2026, was supported by key stakeholders including ClearCardio(TM), company leadership, and institutional investors. The funds will be used to commercialize HeartBeam's FDA-cleared 12-lead synthesized ECG system, further develop its extended-wear patch and heart attack detection technologies, expand AI capabilities, and for general corporate purposes.
The company's platform technology is designed to collect ECG signals in 3D from three non-coplanar directions and synthesize them into a 12-lead ECG. This cable-free device is intended for portable use, allowing physicians to identify cardiac health trends and acute conditions outside of a medical facility. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025. The company holds over 20 issued patents related to its technology.
This capital raise positions HeartBeam to advance the commercialization of its innovative cardiac monitoring solutions, potentially transforming the detection and management of critical cardiac conditions. The funding will support the company's efforts to bring its technology to a broader market, enabling patients to receive actionable heart intelligence wherever they are. For more details on the offering, visit https://ibn.fm/9iNYY.
